Dennis M. Lanfear - Nov 22, 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
President & CEO, Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Stock symbol
CHRS
Transactions as of
Nov 22, 2023
Transactions value $
-$24,755
Form type
4
Date filed
11/24/2023, 04:04 PM
Previous filing
Jun 15, 2023
Next filing
Jan 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Options Exercise $58.1K +41K +6.26% $1.42 696K Nov 22, 2023 Direct F1
transaction CHRS Common Stock Options Exercise $367K +259K +37.21% $1.42 955K Nov 22, 2023 Direct F2
transaction CHRS Common Stock Sale -$450K -223K -23.37% $2.02 732K Nov 22, 2023 Direct F2, F3
holding CHRS Common Stock 433K Nov 22, 2023 By Trust F4
holding CHRS Common Stock 87K Nov 22, 2023 By LLC F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 -300K -100% $0.00* 0 Nov 22, 2023 Common Stock 300K $1.42 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 For part of the stock option, this represents a cash exercise-and-hold transaction where cash was paid by the Reporting Person for the exercise price and anticipated taxes.
F2 For the remaining part of the stock option, this represents a cashless exercise-and-hold transaction where only enough shares were sold to cover the exercise price, anticipated taxes and broker's fee, and the remaining shares were held by the Reporting Person.
F3 This transaction was executed in multiple trades at prices ranging from $2.000 to $2.055. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F5 These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F6 The underlying shares subject to the option vested and became exercisable in successive, equal monthly installments over four years measured from July 20, 2013.